Rosen's Breast Pathology, 4e

405

Ductal Carcinoma In Situ

122. Singh N, Theaker JM. Calcium oxalate crystals (Weddellite) within the secretions of ductal carcinoma in situ —a rare phenomenon. J Clin Pathol 1999;52:145–146. 123. Lomme MM, Steinhoff MM. Intraluminal crystalloids in benign breast ducts. Breast J 2005;11:510. 124. Mayr NA, Staples JJ, Robinson RA, et al. Morphometric studies in in- traductal breast carcinoma using computerized image analysis. Cancer 1991;67:2805–2812. 125. Lindley R, Bulman A, Parsons P, et al. Histologic features predictive of an increased risk of early local recurrence after treatment of breast cancer by local tumor excision and radical radiotherapy. Surgery 1989;105:13–20. 126. Bodis S, Siziopikou KP, Schnitt SJ, et al. Extensive apoptosis in ductal carcinoma in situ of the breast. Cancer 1996;77:1831–1835. 127. Harn HJ, Shen KL, Yueh KC, et al. Apoptosis occurs more frequently in intraductal carcinoma than in infiltrating duct carcinoma of hu- man breast cancer and correlates with altered p53 expression: detected by terminal-deoxynucleotidyl-transferase-mediated dUTP-FITC nick end labelling (TUNEL). Histopathology 1997;31:534–539. 128. Quinn CM, Ostrowski JL, Harkins L, et al. Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins. Histo- pathology 1998;33:531–536. 129. Sneige N, Lagios MD, Schwarting R, et al. Interobserver reproducibil- ity of the Lagios nuclear grading system for ductal carcinoma in situ . Hum Pathol 1999;30:257–262. 130. Muir R, Aitkenhead AC. The healing of intraduct carcinoma of the mamma. J Pathol Bacteriol 1934;38:117–127. 131. Davies JD. Hyperelastosis, obliteration and fibrous plaques in major ducts of the human breast. J Pathol 1973;110:13–26. 132. Kim HS, Kim GY, Kim YW, et al. Stromal CD10 expression and rela- tionship to the E-cadherin/beta-catenin complex in breast carcinoma. Histopathology 2010;56:708–719. 133. Witkiewicz AK, Freydin B, Chervoneva I, et al. Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients pre- dicts disease recurrence. Cancer Biol Ther 2010;10:391–396. 134. Bagaria SP, Shamonki J, Kinnaird M, et al. The florid subtype of lobu- lar carcinoma in situ : marker of precursor for invasive lobular carci- noma. Ann Surg Oncol 2011;18:1845–1851. 135. de Deus Moura R, Wludarski SC, Carvalho FM, et al. Immunohis- tochemistry applied to the differential diagnosis between ductal and lobular carcinoma of the breast. Appl Immunohistochem Mol Morphol 2013;21:1–12. 136. Chan JKC, Ng WF. Sclerosing adenosis cancerized by intraductal car- cinoma. Pathology 1987;19:425–428. 137. Eusebi V, Collina G, Bussolati G. Carcinoma in situ in sclerosing adenosis of the breast: an immunocytochemical study. Semin Diagn Pathol 1989;6:146–152. 138. Oberman HA, Markey BA. Non-invasive carcinoma of the breast pre- senting in adenosis. Mod Pathol 1991;4:31–35. 139. Ichihara S, Aoyama H. Intraductal carcinoma of the breast arising in sclerosing adenosis. Case report. Pathol Int 1994;44:722–726. 140. Moritani S, Ichihara S, Hasegawa M, et al. Topographical, morpho- logical and immunohistochemical characteristics of carcinoma in situ of the breast involving sclerosing adenosis. Two distinct topographical patterns and histological types of carcinoma in situ . Histopathology 2011;58:835–846. 141. Taylor HB, Norris HJ. Epithelial invasion of nerves in benign diseases of the breast. Cancer 1967;20:2245–2249. 142. Tsang WYW, Chan JKC. Neural invasion in intraductal carcinoma of the breast. Hum Pathol 1992;23:202–204. 143. Bianchi S, Giannotti E, Vanzi E, et al. Radial scar without associated atypical epithelial proliferation on image-guided 14-gauge needle core biopsy: analysis of 49 cases from a single-centre and review of the lit- erature. Breast 2012;21:159–164. 144. Resetkova E, Edelweiss M, Albarracin CT, et al. Management of radial sclerosing lesions of the breast diagnosed using percutaneous vac- uum-assisted core needle biopsy: recommendations for excision based on seven years of experience at a single institution. Breast Cancer Res Treat 2011;127:335–343. 145. Rosen PP. Coexistent lobular carcinoma in situ and intraductal carci- noma in a single lobular-duct unit. Am J Surg Pathol 1980;4:241–246. 146. Dundar MM, Badve S, Bilgin G, et al. Computerized classification of intraductal breast lesions using histopathological images. IEEE Trans Biomed Eng 2011;58:1977–1984.

147. Collins LC, Tamimi RM, Baer HJ, et al. Outcome of patients with duc- tal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses’ Health Study. Cancer 2005;103:1778–1784. 148. Sanders ME, Schuyler PA, Dupont WD, et al. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 2005;103:2481–2484. 149. Goldstein NS, Murphy TM. Intraductal carcinoma associated with in- vasive carcinoma of the breast: a comparison of the two lesions with implications for intraductal carcinoma classification systems. Am J Clin Pathol 1996;106:312–318. 150. Shoker BS, Sloane JP. DCIS grading schemes and clinical implications. Histopathology 1999;35:393–400. 151. The Consensus Conference Committee. Consensus Conference on the classification of ductal carcinoma in situ . Cancer 1997;80:1798–1802. 152. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal- like phenotype: a possible precursor to invasive basal-like breast can- cer. Mod Pathol 2006;19:617–621. 153. Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast ductal carcinoma- in-situ . Lancet 1995;345:1154–1157. 154. Silverstein MJ, Lagios MD, Craig PH, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996;77:2267–2274. 155. Douglas-Jones AG, Gupta SK, Attanoos RL, et al. A critical appraisal of six modern classifications of ductal carcinoma in situ of the breast (DCIS): correlation with grade of associated invasive carcinoma. His- topathology 1996;29:397–409. 156. Sloane JP, Amendoeira I, Apostolikas N, et al. Consistency achieved by 23 European pathologists in categorizing ductal carcinoma in situ of the breast using five classifications. European Commis- sion Working Group on Breast Screening Pathology. Hum Pathol 1998;29:1056–1062. 157. Scott MA, Lagios MD, Axelsson K, et al. Ductal carcinoma in situ of the breast: reproducibility of histological subtype analysis. Hum Pathol 1997;28:967–973. 158. Schuh F, Biazús JV, Resetkova E, et al. Reproducibility of three clas- sification systems of ductal carcinoma in situ of the breast using a web- based survey. Pathol Res Pract 2010;206:705–711. 159. Pinder SE, Duggan C, Ellis IO, et al. A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. Br J Cancer 2010;103:94–100. 160. Balleine RL, Webster LR, Davis S, et al. Molecular grading of ductal carcinoma in situ of the breast. Clin Cancer Res 2008;14: 8244–8252. 161. Ottinetti A, Sapino A. Morphometric evaluation of microvessels sur- rounding hyperplastic and neoplastic mammary lesions. Breast Can- cer Res Treat 1988;11:241–248. 162. Tamaki K, Sasano H, Maruo Y, et al. Vasohibin-1 as a potential pre- dictor of aggressive behavior of ductal carcinoma in situ of the breast. Cancer Sci 2010;101:1051–1058. 163. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis—correlation in invasive breast cancer. N Engl J Med 1991;324:1–8. 164. Guidi AJ, Fischer L, Harris JR, et al. Microvessel density and distri- bution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 1994;86:614–619. 165. Heffelfinger SC, Yassin R, Miller MA, et al. Vascularity of prolifera- tive breast disease and carcinoma in situ correlates with histological features. Clin Cancer Res 1996;2:1873–1878. 166. Guidi AJ, Schnitt SJ. Angiogenesis in preinvasive lesions of the breast. Breast J 1996;2:364–369. 167. Engels K, Fox SB, Whitehouse RM, et al. Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast. J Pathol 1997;181:207–212. 168. Sternlicht MD, Barksy SH. The myoepithelial defense: a host defense against cancer. Med Hypotheses 1997;48:37–46. 169. Barsky SH, Nguyen M, Grossman DA, et al. Myoepithelial cells limit DCIS metastasis by blocking invasion and angiogenesis. Mod Pathol 1997;10:16A. 170. Basset P, Okada A, Chenard MP, et al. Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic impli- cations. Matrix Biol 1997;15:535–541. 171. Sternlicht MD, Safarians S, Rivera SP, et al. Characterizations of the extracellular matrix and proteinase inhibitor content of human myo- epithelial tumors. Lab Invest 1996;74:781–796.